PF-Atlasניסויים קליניים › NCT06573164

Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis

Bacillus clausii tablets(Qipian®) · לא צוין

מזהה רישום
NCT06573164
שלב
לא צוין
סטטוס
הושלם
תרופה / התערבות
Bacillus clausii tablets(Qipian®)
ממן
Second Affiliated Hospital, School of Medicine, Zhejiang University
התחלה
2024-01-01
מספר משתתפים
60
מיקומים
1

על הניסוי

Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma(ARIA) and Global Initiative for Asthma(GINA) diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

צפו ב-NCT06573164 ב-ClinicalTrials.gov ←

קישורים קשורים

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT06573164 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.